| Richelle J Koopman, MD | |
|
2325 Smiley Ln, Columbia, MO 65202-1947 | |
| (573) 884-8980 | |
| (573) 884-0040 |
| Full Name | Richelle J Koopman |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 31 Years |
| Location | 2325 Smiley Ln, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003924960 | NPI | - | NPPES |
| 200587400 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2007021707 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Missouri Health Care | Columbia, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
News Archive
UT Southwestern Medical Center researchers have developed a classification for cancers caused by KRAS, the most frequently mutated gene in cancer, that could eventually help oncologists choose more effective, customized cancer therapies.
Just like snowflakes, no two people are alike, even if they're identical twins according to new genetic research from The University of Western Ontario. Molecular geneticist Shiva Singh has been working with psychiatrist Dr. Richard O'Reilly to determine the genetic sequencing of schizophrenia using identical or monozygotic twins. The study is published in this month's PLoS ONE.
Cancer is usually attributed to faulty genes, but growing evidence from the field of cancer epigenetics indicates a key role for the gene "silencing" proteins that stably turn genes off inside the cell nucleus. A new study from Rice University and Baylor College of Medicine promises to speed research in the field by rapidly identifying the genes that epigenetic proteins can target for silencing.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
› Verified 4 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
UT Southwestern Medical Center researchers have developed a classification for cancers caused by KRAS, the most frequently mutated gene in cancer, that could eventually help oncologists choose more effective, customized cancer therapies.
Just like snowflakes, no two people are alike, even if they're identical twins according to new genetic research from The University of Western Ontario. Molecular geneticist Shiva Singh has been working with psychiatrist Dr. Richard O'Reilly to determine the genetic sequencing of schizophrenia using identical or monozygotic twins. The study is published in this month's PLoS ONE.
Cancer is usually attributed to faulty genes, but growing evidence from the field of cancer epigenetics indicates a key role for the gene "silencing" proteins that stably turn genes off inside the cell nucleus. A new study from Rice University and Baylor College of Medicine promises to speed research in the field by rapidly identifying the genes that epigenetic proteins can target for silencing.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richelle J Koopman, MD Po Box 843966, Kansas City, MO 64184-3966 Ph: (573) 884-3300 | Richelle J Koopman, MD 2325 Smiley Ln, Columbia, MO 65202-1947 Ph: (573) 884-8980 |
News Archive
UT Southwestern Medical Center researchers have developed a classification for cancers caused by KRAS, the most frequently mutated gene in cancer, that could eventually help oncologists choose more effective, customized cancer therapies.
Just like snowflakes, no two people are alike, even if they're identical twins according to new genetic research from The University of Western Ontario. Molecular geneticist Shiva Singh has been working with psychiatrist Dr. Richard O'Reilly to determine the genetic sequencing of schizophrenia using identical or monozygotic twins. The study is published in this month's PLoS ONE.
Cancer is usually attributed to faulty genes, but growing evidence from the field of cancer epigenetics indicates a key role for the gene "silencing" proteins that stably turn genes off inside the cell nucleus. A new study from Rice University and Baylor College of Medicine promises to speed research in the field by rapidly identifying the genes that epigenetic proteins can target for silencing.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
› Verified 4 days ago
Nicholas Michael Lefevre, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 551 E Southampton Dr, Columbia, MO 65201 Phone: 573-884-7733 Fax: 573-882-6228 | |
Susan Z. John, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 909 Hitt St, Columbia, MO 65211 Phone: 573-882-7481 Fax: 573-882-5370 | |
Dr. Christopher Joseph Sporleder, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 | |
Dr. Christopher D. Farmer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 S Keene St, Columbia, MO 65201 Phone: 573-443-2402 Fax: 573-443-0574 | |
David D Cravens, MD, MSPH, CMD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: One Hospital Drive, Columbia, MO 65201 Phone: 573-884-7733 Fax: 573-884-5559 | |
Dr. Shannon Rhea Sitzmann, DNP, APRN, FNP-BC Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2900 Trimble Rd Ste 107, Columbia, MO 65201 Phone: 573-818-3067 |